Context Therapeutics has acquired CT-95, a bispecific antibody drug previously owned by Link Immunotherapeutics, for an undisclosed amount.
CT-95, now added to Context Therapeutics' portfolio, is a potentially first-in-class mesothelin x CD3 T cell-engaging bispecific antibody. It has received Investigational New Drug (IND) clearance from the FDA and is claimed to have high potential in treating several underserved solid cancers, including ovarian, lung, and pancreatic. Following the acquisition, Context Therapeutics plans to begin clinical trials for the drug, which, along with the acquisition, are planned to be funded using its existing cash reserves.
Context Therapeutics is a biopharmaceutical company that develops novel treatments for solid tumors. The company's primary focus is on CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target CLDN6-positive tumors. Such tumors include ovarian, endometrial, testicular, and lung cancers, where CLDN6 is present in high concentrations but is minimally expressed in healthy adult tissues. The company aims to advance CTIM-76 through to clinical development, with a Phase I clinical trial expected to begin in mid-2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.